GlassScriptPhysician profile
Shannah D Click
NPI 1245841063
$1,680.00
in general payments reported to CMS, 2019-2025
30 companies · $165 in 2025
The $165 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $52.14 · 2023: $755 · 2024: $707 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,627.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $291.76 | 2023-2024 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $182.84 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Tandem Diabetes Care, INC. | $143.58 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $120.82 | 2024 | Dexcom G6 Transmitter |
| Cequr Corporation | $109.70 | 2023 | Cequr Simplicity |
| Recordati_rare_diseases_inc. | $83.64 | 2023-2024 | Isturisa |
| Xeris Pharmaceuticals, INC. | $80.91 | 2023 | Gvoke Hypopen |
| Radius Health, INC. | $70.85 | 2023 | Tymlos |
| Amgen INC. | $65.55 | 2023 | Evenity, Prolia |
| Novo Nordisk INC | $48.39 | 2024-2025 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $38.76 | 2023-2024 | |
| Azurity Pharmaceuticals, INC. | $35.73 | 2023-2025 | Adthyza, Azmiro |
| Ascensia Diabetes Care US INC. | $31.37 | 2024-2025 | |
| Antares Pharma, INC. | $31.35 | 2024 | Xyosted |
| Corcept Therapeutics | $30.04 | 2024 | Korlym |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $28.98 | 2024 | Senza |
| Horizon Therapeutics Plc | $28.54 | 2023 | Tepezza |
| Echosens North America, INC. | $25.24 | 2024 | Fibroscan |
| Medtronic, INC. | $24.11 | 2023 | Minimed 780g |
| Amryt Pharma Holdings LTD | $22.20 | 2023 | Mycapssa |
| Novartis Pharmaceuticals Corporation | $21.48 | 2022 | |
| Insulet Corporation | $20.92 | 2025 | Omnipod |
| Kyowa Kirin, INC. | $20.73 | 2023 | |
| Chiesi USA, INC. | $20.10 | 2024 | Mycapssa |
| Halozyme INC | $19.20 | 2023 | |
| Alnylam Pharmaceuticals INC. | $18.38 | 2025 | Givlaari |
| Ascendis Pharma Endocrinology INC | $17.99 | 2025 | Yorvipath |
| Amneal Pharmaceuticals LLC | $17.09 | 2024 | Unithroid |
| Sanofi-Aventis U.S. LLC | $15.72 | 2023 | |
| Abbvie INC. | $14.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannah Click listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.